Immunovative Therapies Ltd and its US subsidiary Mirror Biologics Inc. are testing a novel, T cell-based vaccination concept that might protect risk groups from new SARS-CoV-2 variants and any emerging viral pandemic in the future. However, therapies that significantly reduce the mortality rate of COVID-19 patients may be a cheaper way compared to vaccines to protect high-risk groups. UK researchers reported on the first therapy in mid-June.

UK-Austrian fungal infection specialist F2G Ltd has secured a €50.8m (US $60.8m) financing from new and existing investors.

COVID-19 has put life science research companies into the limelight. An Interview with Raimund Gabriel, founder and managing director MC Services AG, on the role of corporate communications in the corona crisis.

An ongoing crisis and evolving new working habits of industry executives call for an entirely new and up-to-date partnering format. Workarounds such as moving a partnering event’s scheduled one-on-one meetings online is neither imaginative nor does it meet the requirements of flexibility and effectiveness. The format presented here sounds the bell for a new era of pharma partnering.